Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 3
1954 4
1955 6
1957 2
1964 1
1965 3
1966 15
1967 11
1968 24
1969 19
1970 25
1971 22
1972 31
1973 39
1974 35
1975 28
1976 29
1977 21
1978 19
1979 26
1980 33
1981 29
1982 27
1983 25
1984 30
1985 29
1986 31
1987 15
1988 15
1989 26
1990 24
1991 19
1992 27
1993 15
1994 18
1995 21
1996 15
1997 28
1998 15
1999 19
2000 26
2001 28
2002 19
2003 40
2004 38
2005 22
2006 39
2007 37
2008 57
2009 53
2010 60
2011 64
2012 60
2013 53
2014 53
2015 62
2016 55
2017 65
2018 64
2019 56
2020 61
2021 57
2022 74
2023 53
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

1,891 results

Results by year

Filters applied: . Clear all
Page 1
The health effects of vitamin D supplementation: evidence from human studies.
Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, Richards JB. Bouillon R, et al. Nat Rev Endocrinol. 2022 Feb;18(2):96-110. doi: 10.1038/s41574-021-00593-z. Epub 2021 Nov 23. Nat Rev Endocrinol. 2022. PMID: 34815552 Free PMC article. Review.
However, the causal link between vitamin D and many extra-skeletal outcomes remains unclear. The VITAL, ViDA and D2d randomized clinical trials (combined number of participants >30,000) indicated that vitamin D supplementation of vitamin D-replete adults (baselin …
However, the causal link between vitamin D and many extra-skeletal outcomes remains unclear. The VITAL, ViDA and D2d randomized cl …
Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions.
Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, Lips P, Munns CF, Lazaretti-Castro M, Giustina A, Bilezikian J. Bouillon R, et al. Endocr Rev. 2019 Aug 1;40(4):1109-1151. doi: 10.1210/er.2018-00126. Endocr Rev. 2019. PMID: 30321335 Free PMC article. Review.
The etiology of endemic rickets was discovered a century ago. Vitamin D is the precursor of 25-hydroxyvitamin D and other metabolites, including 1,25(OH)2D, the ligand for the vitamin D receptor (VDR). ...From observational studies in human subjects, poor vitamin D status …
The etiology of endemic rickets was discovered a century ago. Vitamin D is the precursor of 25-hydroxyvitamin D and other metabolites …
Rickets, Vitamin D, and Ca/P Metabolism.
Miller WL, Imel EA. Miller WL, et al. Horm Res Paediatr. 2022;95(6):579-592. doi: 10.1159/000527011. Epub 2022 Nov 29. Horm Res Paediatr. 2022. PMID: 36446330 Free article. Review.
Rickets was a major public health problem dating from Roman times, and medical descriptions of rickets date from the 17th century. ...Autosomal dominant hypophosphatemic rickets similarly led to the discovery of FGF23, a phosphate-wasting humoral factor made …
Rickets was a major public health problem dating from Roman times, and medical descriptions of rickets date from the 17th cent …
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Imel EA, et al. Lancet. 2019 Jun 15;393(10189):2416-2427. doi: 10.1016/S0140-6736(19)30654-3. Epub 2019 May 16. Lancet. 2019. PMID: 31104833 Free PMC article. Clinical Trial.
METHODS: In this randomised, active-controlled, open-label, phase 3 trial at 16 clinical sites, we enrolled children with X-linked hypophosphataemia aged 1-12 years. ...Three serious adverse events occurred in each group, all considered unrelated to treatment …
METHODS: In this randomised, active-controlled, open-label, phase 3 trial at 16 clinical sites, we enrolled children wi …
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D. Haffner D, et al. Pediatr Nephrol. 2022 Oct;37(10):2289-2302. doi: 10.1007/s00467-022-05505-5. Epub 2022 Mar 29. Pediatr Nephrol. 2022. PMID: 35352187 Free PMC article.
Here, we discuss the management of different forms of rickets, including new therapeutic approaches based on recent guidelines. ...Treatment of phosphopenic rickets depends on the underlying pathophysiology. Fibroblast-growth factor 23 (FGF23)-associated hypophospha …
Here, we discuss the management of different forms of rickets, including new therapeutic approaches based on recent guidelines. ...Tr …
Vitamin D in Toddlers, Preschool Children, and Adolescents.
Taylor SN. Taylor SN. Ann Nutr Metab. 2020;76 Suppl 2:30-41. doi: 10.1159/000505635. Epub 2020 Nov 24. Ann Nutr Metab. 2020. PMID: 33232959 Free article. Review.
SUMMARY: Observational studies have pointed to a vitamin D status, as indicated by a 25-hydroxyvitamin D concentration, of 50 nmol/L to ensure avoidance of rickets and of 75 nmol/L to optimize health. However, the benefits of achieving these levels of vitamin D status are …
SUMMARY: Observational studies have pointed to a vitamin D status, as indicated by a 25-hydroxyvitamin D concentration, of 50 nmol/L to ensu …
Refractory Rickets.
Chinoy A, Padidela R. Chinoy A, et al. Indian J Pediatr. 2023 Jun;90(6):574-581. doi: 10.1007/s12098-023-04538-4. Epub 2023 Apr 19. Indian J Pediatr. 2023. PMID: 37074534 Free PMC article. Review.
Nutritional rickets, caused by vitamin D and/or calcium deficiency is by far the most common cause of rickets. In resource-limited settings, it is therefore not uncommon to treat rickets with vitamin D and calcium. If rickets fails to heal and/or if th …
Nutritional rickets, caused by vitamin D and/or calcium deficiency is by far the most common cause of rickets. In resource-lim …
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, Högler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA. Ward LM, et al. J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3241-e3253. doi: 10.1210/clinem/dgac296. J Clin Endocrinol Metab. 2022. PMID: 35533340 Free PMC article. Clinical Trial.
The main outcome measure included the least squares means difference (LSMD) in Radiographic Global Impression of Change (RGI-C) rickets total score from baseline to week 64. RESULTS: The LSMD in outcomes through 64 weeks on burosumab vs conventional therapy by age group we …
The main outcome measure included the least squares means difference (LSMD) in Radiographic Global Impression of Change (RGI-C) rickets …
Hypophosphatemic Rickets.
Bitzan M, Goodyer PR. Bitzan M, et al. Pediatr Clin North Am. 2019 Feb;66(1):179-207. doi: 10.1016/j.pcl.2018.09.004. Pediatr Clin North Am. 2019. PMID: 30454743 Review.
Hypophosphatemic rickets, mostly of the X-linked dominant form caused by pathogenic variants of the PHEX gene, poses therapeutic challenges with consequences for growth and bone development and portends a high risk of fractions and poor bone healing, dental problems and ne …
Hypophosphatemic rickets, mostly of the X-linked dominant form caused by pathogenic variants of the PHEX gene, poses therapeutic chal …
Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A, Imel EA, Whyte MP, Portale AA, Högler W, Boot AM, Padidela R, Van't Hoff W, Gottesman GS, Chen A, Skrinar A, Scott Roberts M, Carpenter TO. Linglart A, et al. J Clin Endocrinol Metab. 2022 Feb 17;107(3):813-824. doi: 10.1210/clinem/dgab729. J Clin Endocrinol Metab. 2022. PMID: 34636899 Free PMC article. Clinical Trial.
We have previously reported outcomes up to 64 weeks, and here we report safety and efficacy follow-up results up to 160 weeks from an open-label, multicenter, randomized, dose-finding trial of burosumab for 5- to 12-year-old children with XLH. ...From week 66 to wee …
We have previously reported outcomes up to 64 weeks, and here we report safety and efficacy follow-up results up to 160 weeks from an open-l …
1,891 results